Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device Journal Article
| Authors: | McThenia, S. S.; Pandit-Taskar, N.; Grkovski, M.; Donzelli, M. A.; Diagana, S.; Greenfield, J. P.; Souweidane, M. M.; Kramer, K. |
| Article Title: | Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device |
| Abstract: | Purpose: Programmable ventriculoperitoneal shunts (pVP shunts) are increasingly utilized for intraventricular chemotherapy, radioimmunotherapy, and/or cellular therapy. Shunt adjustments allow optimization of drug concentrations in the thecal space with minimization in the peritoneum. This report assesses the success of the pVP shunt as an access device for intraventricular therapies. Quantifying intrathecal drug delivery using scintigraphy by pVP shunt model has not been previously reported. Methods: We performed a single-institution, retrospective analysis on patients with CNS tumors and pVP shunts from 2003 to 2020, noting shunt model. pVP flow was evaluated for consideration of compartmental radioimmunotherapy (cRIT) using In-111-DTPA scintigraphy. Scintigraphy studies at 2–4 h and at 24 h quantified ventricular-thecal and peritoneal drug activity. Results: Twenty-two CSF flow studies were administered to 15 patients (N = 15) with diagnoses including medulloblastoma, metastatic neuroblastoma, pineoblastoma, and choroid plexus carcinoma. Six different types of pVP models were noted. 100% of the studies demonstrated ventriculo-thecal drug activity. 27% (6 of 22) of the studies had no peritoneal uptake visible by imaging. 73% (16 of 22) of the studies had minimal relative peritoneal uptake (< 12%). 27% (6 of 22) of the studies demonstrated moderate relative peritoneal uptake (12–37%). No studies demonstrated peritoneal uptake above 37%. Conclusions: All patients had successful drug delivery of In-111-DTPA to the ventriculo-thecal space. 73% of the patients had minimal relative (< 12%) peritoneal drug uptake. Though efficacy varies by shunt model, low numbers preclude conclusions regarding model superiority. CSF flow scintigraphy studies assesses drug distribution of In-111-DTPA, informing CSF flow for delivery of intraventricular therapies. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | retrospective studies; brain tumor; retrospective study; cerebellar neoplasms; brain ventricle peritoneum shunt; drug delivery; hydrocephalus; adverse event; cerebellum tumor; pentetic acid; intraventricular; peritoneal; ventriculoperitoneal shunt; humans; human; thecal |
| Journal Title: | Journal of Neuro-Oncology |
| Volume: | 157 |
| Issue: | 3 |
| ISSN: | 0167-594X |
| Publisher: | Springer |
| Date Published: | 2022-05-01 |
| Start Page: | 457 |
| End Page: | 463 |
| Language: | English |
| DOI: | 10.1007/s11060-022-03989-7 |
| PUBMED: | 35403968 |
| PROVIDER: | scopus |
| PMCID: | PMC11292655 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work